Transformational year delivered strong revenue growth of 190% quarter-over-quarter and 171% full year-over-full year DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2021 and provided a corporate and...
|
Company to host conference call and webcast on Tuesday, March 22, at 8:30 am ET DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and full year ended...
|
New clients continue Dario's track record of success in winning employer and provider business DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new agreements with a regional employer and a regional provider. The contracts are...
|
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 42nd Annual Healthcare Conference, which...
|
Mar 1, 2022 Novel Strategic Agreement Focuses on Commercial Growth for Dario and the Development of Digital Health Solutions on Dario's Platform DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare...
|
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive agreements with institutional...
|
New peer-reviewed study sheds light on the effectiveness of an integrated approach for Dario users with both diabetes and high blood pressure. DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing...
|
New contracts expand Dario's footprint to more than 40 clients in the employer market DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new...
|
Jan 20, 2022 Dario's third all-equity acquisition in the last 12 months brings cutting edge vision technology to the company's comprehensive digital therapeutics platform DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market (the Company), announced it has entered into an agreement to purchase all of the right, title and...
|
New Partnership Expands Dario's Payer Presence with First Contract for Managed Medicaid DarioHealth Corp. (NASDAQ-CM: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has contracted with a large regional health plan (the "Plan") to deliver its...
|
Webinar to be held Wednesday, January 19th at 8am ET DarioHealth Corp. (Nasdaq: DRIO) a leader in the global digital therapeutics (DTx) market, today announced that it will host an investor webinar on navigating the emerging digital health trends in...
|
Dario's new employer clients include a contract for its full suite of digital therapeutic solutions DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in...
|
| |